LENZ Therapeutics, a late-stage biopharmaceutical company focused on developing and commercializing innovative therapies to improve vision, and Graphite Bio, Inc. (NASDAQ: GRPH) announce that they have entered into a definitive merger agreement to combine the companies in an all-stock transaction. The lead programs of the combined company will address presbyopia, the inevitable loss of near vision that impacts the daily lives of nearly all people over the age of 45. The combined company is expected to trade on Nasdaq under the ticker symbol “LENZ.”
Read the full article: LENZ Therapeutics and Graphite Bio Announce Merger Agreement //
Source: https://www.businesswire.com/news/home/20231115881807/en/LENZ-Therapeutics-and-Graphite-Bio-Announce-Merger-Agreement